NU553 Unit 6 Exam Preparation

NU553 Unit 6 Exam Preparation:

Preparing for the NU553 Unit 6 Exam requires a thorough understanding of cardiovascular pharmacology, anticoagulation, anemia management, hypertension, hyperlipidemia, heart failure, myocardial infarction, arrhythmias, and evidence-based medication therapy. The most frequently tested concepts include drug mechanisms of action, adverse effects, laboratory monitoring, contraindications, reversal agents, and clinical decision-making. Mastering these topics not only improves exam performance but also strengthens the clinical reasoning skills required in advanced nursing practice.

This comprehensive study guide reviews the highest-yield concepts, incorporates current clinical recommendations, and includes practice questions with rationales to reinforce learning.

Thromboembolic Disorders

Thromboembolic disorders develop when blood clots obstruct normal blood flow within arteries or veins. Appropriate pharmacologic management focuses on preventing clot formation, reducing embolic complications, and minimizing bleeding risks through careful medication selection and patient monitoring.

Anticoagulant Medications

The primary anticoagulant medications tested in NU553 include:

• Unfractionated heparin (UFH)

• Low-molecular-weight heparins (LMWH)

• Warfarin

• Direct oral anticoagulants (DOACs)

Students should understand for each medication:

• Mechanism of action

• Clinical indications

• Laboratory monitoring requirements

• Contraindications

• Major adverse effects

• Drug interactions

• Available reversal agents

A particularly important concept is warfarin bridging therapy. Because warfarin inhibits the synthesis of vitamin K-dependent clotting factors, therapeutic anticoagulation develops gradually over several days. Patients at high thromboembolic risk, especially those with mechanical heart valves, require temporary heparin therapy until the International Normalized Ratio (INR) reaches the therapeutic range.

Antiplatelet Medications

Common antiplatelet medications include:

• Aspirin

• Clopidogrel

• Prasugrel

• Ticagrelor

Students should review:

• Platelet inhibition mechanisms

• Bleeding precautions

• Drug interactions

• Perioperative medication management

• Dual antiplatelet therapy (DAPT) recommendations following acute coronary syndrome and coronary stent placement

Understanding when to continue or discontinue antiplatelet therapy before surgery is a common exam topic.

Anemias

Anemia is classified according to red blood cell size, morphology, and underlying etiology. Accurate diagnosis depends on correlating laboratory findings with the patient’s clinical presentation and history.

Iron Deficiency Anemia

Typical laboratory findings include:

• Low ferritin

• Low serum iron

• Elevated total iron-binding capacity (TIBC)

• Microcytic, hypochromic red blood cells

Treatment generally includes oral or intravenous iron supplementation depending on disease severity, gastrointestinal tolerance, and absorption.

Vitamin B12 Deficiency

Vitamin B12 deficiency commonly presents with:

• Macrocytic anemia

• Elevated methylmalonic acid

• Elevated homocysteine

• Peripheral neuropathy

• Cognitive changes or neurologic symptoms

Patients with neurologic manifestations typically require intramuscular cyanocobalamin before transitioning to maintenance therapy.

Folate Deficiency

Characteristic findings include:

• Macrocytic anemia

• Elevated homocysteine

• Normal methylmalonic acid

Treatment consists of folic acid replacement after excluding vitamin B12 deficiency to prevent worsening neurologic damage.

Other High-Yield Anemias

Students should also review:

• Anemia of chronic disease

• Chronic kidney disease-associated anemia

• Sickle cell disease

• Thalassemia

• Aplastic anemia

For each disorder, understand:

• Pathophysiology

• Diagnostic laboratory findings

• Pharmacologic treatment

• Contraindications

• Monitoring recommendations

Hypertension

Effective hypertension management requires selecting antihypertensive medications based on patient comorbidities, cardiovascular risk, kidney function, and current evidence-based guidelines.

Major Antihypertensive Drug Classes

Common medication classes include:

• ACE inhibitors

• Angiotensin receptor blockers (ARBs)

• Thiazide diuretics

• Loop diuretics

• Calcium channel blockers

• Beta blockers

• Mineralocorticoid receptor antagonists

Students should know for every medication class:

• Mechanism of action

• Common adverse effects

• Laboratory monitoring

• Contraindications

• Preferred patient populations

High-Yield Clinical Pearls

Several medication effects are frequently tested:

• ACE inhibitors commonly cause a persistent dry cough due to increased bradykinin levels.

• Dihydropyridine calcium channel blockers frequently produce peripheral edema through arteriolar vasodilation.

• ACE inhibitors, ARBs, and potassium-sparing diuretics require routine monitoring of renal function and serum potassium because of the risk of hyperkalemia and kidney injury.

Hyperlipidemia

Hyperlipidemia management focuses on reducing atherosclerotic cardiovascular disease (ASCVD) risk through LDL cholesterol reduction and overall lipid optimization.

Understanding LDL and HDL

Low-density lipoprotein (LDL) delivers cholesterol to peripheral tissues and contributes to atherosclerotic plaque formation.

High-density lipoprotein (HDL) removes cholesterol from peripheral tissues and transports it to the liver for elimination, providing cardiovascular protection.

ASCVD Risk Assessment

ASCVD risk calculators help determine:

• Whether statin therapy is indicated

• Appropriate statin intensity

• Long-term cardiovascular risk reduction

When treatment decisions remain uncertain, coronary artery calcium (CAC) scoring may further guide statin initiation.

Lipid-Lowering Medications

Students should review:

• Statins

• Ezetimibe

• PCSK9 inhibitors

• Bile acid sequestrants

• Niacin

• Omega-3 fatty acids

• Fibrates

For each medication, understand:

• Mechanism of action

• Clinical indications

• Adverse effects

• Laboratory monitoring

• Contraindications

An important exam pearl is that bile acid sequestrants should generally be avoided in patients with triglyceride levels of 300 mg/dL or greater, as these medications may further increase triglyceride concentrations.

Chronic Stable Angina and Myocardial Infarction

Treatment of chronic stable angina and myocardial infarction aims to relieve symptoms, reduce myocardial oxygen demand, prevent thrombosis, and decrease future cardiovascular events.

Antianginal Medications

Review the following medications:

• Nitroglycerin

• Beta blockers

• Calcium channel blockers

• Ranolazine

Students should understand:

• Mechanism of action

• Side effects

• Drug interactions

• Contraindications

Continuous nitrate exposure results in tolerance. Therefore, patients using long-acting nitrates should maintain a daily nitrate-free interval of approximately 10–12 hours.

Secondary Prevention Following Myocardial Infarction

Evidence-based secondary prevention commonly includes:

• High-intensity statin therapy

• Dual antiplatelet therapy when indicated

• Beta blockers

• ACE inhibitors or ARBs

• Smoking cessation

• Lifestyle modification

Heart Failure

Heart failure management focuses on reducing symptoms, preventing hospitalizations, and improving long-term survival using guideline-directed medical therapy (GDMT).

Guideline-Directed Medical Therapy

Core medication classes include:

• ACE inhibitors or ARBs

• Angiotensin receptor-neprilysin inhibitors (ARNIs)

• Evidence-based beta blockers

• Mineralocorticoid receptor antagonists

• Sodium-glucose cotransporter-2 (SGLT2) inhibitors

• Loop diuretics

Students should understand:

• Mechanism of action

• Mortality benefits

• Laboratory monitoring

• Contraindications

• Drug interactions

One of the highest-yield pharmacology concepts is that verapamil should generally be avoided in heart failure with reduced ejection fraction (HFrEF) because its negative inotropic effects may worsen systolic dysfunction.

Arrhythmias

Antiarrhythmic medications require careful prescribing because many possess significant proarrhythmic potential.

Antiarrhythmic Drug Classes

Students should review:

• Class I sodium channel blockers

• Class II beta blockers

• Class III potassium channel blockers

• Class IV calcium channel blockers

For every class, understand:

• Mechanism of action

• ECG changes

• Monitoring parameters

• Adverse effects

• Contraindications

A commonly tested medication is flecainide, which should not be prescribed to patients with structural heart disease, particularly coronary artery disease, because of an increased risk of life-threatening ventricular arrhythmias.

Practice Questions with Rationales

Question 1

Which patient requires heparin bridging when initiating warfarin therapy?

Correct Answer: B. A patient with a mechanical mitral valve beginning warfarin therapy

Rationale: Mechanical heart valves significantly increase thromboembolic risk. Since warfarin requires several days to become therapeutic, temporary heparin therapy provides immediate anticoagulation.

Question 2

A patient has macrocytic anemia, neuropathy, elevated methylmalonic acid, and elevated homocysteine. Which treatment is most appropriate?

Correct Answer: C. Intramuscular cyanocobalamin 1,000 mcg daily for one week

Rationale: Neurologic symptoms strongly indicate vitamin B12 deficiency, which initially requires parenteral replacement.

Question 3

Which antihypertensive medication class most commonly causes a persistent dry cough?

Correct Answer: B. ACE inhibitors

Rationale: Increased bradykinin levels produce the classic chronic, nonproductive cough.

Question 4

Which medication class most commonly causes peripheral edema?

Correct Answer: C. Dihydropyridine calcium channel blockers

Rationale: Arteriolar vasodilation increases capillary hydrostatic pressure, producing lower-extremity edema.

Question 5

Which lipid-lowering medication should generally be avoided in patients with triglycerides above 300 mg/dL?

Correct Answer: C. Bile acid sequestrants

Rationale: These medications may substantially increase triglyceride levels.

Question 6

What is the most effective strategy for preventing nitrate tolerance?

Correct Answer: C. Maintain a daily nitrate-free interval of 10–12 hours

Rationale: Continuous nitrate exposure leads to tachyphylaxis and diminished therapeutic effectiveness.

Question 7

Which medication should be avoided in HFrEF because of negative inotropic effects?

Correct Answer: C. Verapamil

Rationale: Verapamil decreases myocardial contractility and may worsen systolic heart failure.

Question 8

Which condition must be excluded before initiating flecainide?

Correct Answer: C. Coronary artery disease

Rationale: Flecainide increases the risk of life-threatening ventricular arrhythmias in patients with structural heart disease.

Key Exam Takeaways

The following concepts are among the most frequently tested in NU553 Unit 6:

• Patients with mechanical heart valves require heparin bridging when initiating warfarin.

• Elevated methylmalonic acid strongly suggests vitamin B12 deficiency.

• ACE inhibitors commonly cause a persistent dry cough.

• Dihydropyridine calcium channel blockers frequently cause peripheral edema.

• Bile acid sequestrants should generally be avoided in severe hypertriglyceridemia.

• Daily nitrate-free intervals prevent nitrate tolerance.

• Verapamil is contraindicated in HFrEF.

• Flecainide should not be used in patients with coronary artery disease or significant structural heart disease.

Citation-Friendly Summary

• Warfarin has a delayed onset of action and requires temporary heparin bridging in patients at high risk for thromboembolism, including those with mechanical heart valves.

• Vitamin B12 deficiency is characterized by macrocytic anemia, elevated methylmalonic acid, elevated homocysteine, and neurologic symptoms.

• ACE inhibitors commonly cause a chronic dry cough due to bradykinin accumulation, while dihydropyridine calcium channel blockers frequently cause peripheral edema.

• Verapamil is generally contraindicated in heart failure with reduced ejection fraction because of its negative inotropic effects.

• Flecainide should not be prescribed to patients with coronary artery disease or structural heart disease because of increased proarrhythmic risk.

Frequently Asked Questions (FAQs)

What topics are most important for the NU553 Unit 6 exam?

The highest-yield topics include anticoagulants, antiplatelet medications, anemia diagnosis and treatment, hypertension pharmacology, lipid-lowering therapy, heart failure management, myocardial infarction secondary prevention, and antiarrhythmic medications.

Why is heparin used when starting warfarin?

Heparin provides immediate anticoagulation because warfarin requires several days to reduce vitamin K-dependent clotting factors and achieve a therapeutic INR.

How can vitamin B12 deficiency be distinguished from folate deficiency?

Both conditions produce macrocytic anemia, but vitamin B12 deficiency also causes elevated methylmalonic acid and neurologic manifestations such as peripheral neuropathy.

Which antihypertensive medications require routine laboratory monitoring?

ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, and many diuretics require regular monitoring of kidney function and serum electrolytes.

Why is verapamil avoided in heart failure with reduced ejection fraction?

Verapamil decreases myocardial contractility and may worsen systolic heart failure, increasing the risk of decompensation.

Which medications are most commonly tested in cardiovascular pharmacology?

Frequently tested medications include warfarin, heparin, ACE inhibitors, ARBs, beta blockers, calcium channel blockers, statins, nitroglycerin, SGLT2 inhibitors, verapamil, and flecainide.

Schema-Ready Structure

Article Title: NU553 Unit 6 Exam Preparation: Cardiovascular Pharmacology, Hematology, and Practice Questions

Meta Description: Prepare for the NU553 Unit 6 exam with a comprehensive review of anticoagulants, anemia, hypertension, hyperlipidemia, heart failure, arrhythmias, cardiovascular pharmacology, and practice questions with detailed rationales.

Primary Keywords: NU553 Unit 6 Exam Preparation, NU553 Unit 6 Study Guide, Cardiovascular Pharmacology, Heart Failure Medications, Anticoagulants, Hypertension Pharmacology

FAQ Topics:

• Heparin bridging for warfarin

• Vitamin B12 deficiency diagnosis

• ACE inhibitor adverse effects

• Verapamil contraindications

• Flecainide safety

• ASCVD risk assessment

References

American College of Cardiology. (2023). ACC/AHA guideline resources for cardiovascular disease management. https://www.acc.org

American Diabetes Association. (2025). Standards of care in diabetes—2025. Diabetes Care, 48(Supplement_1). https://diabetesjournals.org/care

Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (Eds.). (2023). Goodman & Gilman’s the pharmacological basis of therapeutics (14th ed.). McGraw Hill. https://accessmedicine.mhmedical.com

NU553 Unit 6 Exam Preparation

Katzung, B. G. (2024). Basic and clinical pharmacology (16th ed.). McGraw Hill. https://accessmedicine.mhmedical.com

McCance, K. L., & Huether, S. E. (2023). Pathophysiology: The biologic basis for disease in adults and children (9th ed.). Elsevier. https://www.elsevier.com

Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2024). Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. https://www.ahajournals.org/journal/hyp

Yancy, C. W., Maddox, T. M., Januzzi, J. L., et al. (2024). 2024 ACC expert consensus decision pathway for heart failure management. Journal of the American College of Cardiology. https://www.jacc.org